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Abstract
Multiple myeloma is a plasma cell cancer that leads to a dysregulated bone remodeling process. We
present a partial differential equation model describing the dynamics of bone remodeling with the presence
of myeloma tumor cells. The model explicitly takes into account the roles of osteoclasts, osteoblasts,
precursor cells, stromal cells, osteocytes, and tumor cells. Previous models based on ordinary differential
equations make the simplifying assumption that the bone and tumor cells are adjacent to each other.
However, in actuality, these cell populations are separated by the bone marrow. Our model takes this
separation into account by including the diffusion of chemical factors across the marrow, which can be
viewed as communication between the tumor and bone. Additionally, this model incorporates the growth
of the tumor and the diminishing bone mass by utilizing a “moving boundary.” We present numerical
simulations that qualitatively validate our model’s description of the cell population dynamics.
1 Introduction
Multiple myeloma is a plasma cell cancer characterized by an excess of malignant plasma cells in the bone
marrow. The disease has a significant impact on the bones, the immune system, and the kidneys (Ameri-
can Cancer Society 2015). In the bone, patients experience pain, hypercalcemia, fractures, and spinal cord
compression (Drake 2014). Spinal cord compression can lead to severe back pain, numbness, and muscle
weakness. Hypercalcemia, or high levels of calcium in the blood, can result in dehydration, excessive uri-
nation, constipation, loss of appetite, weakness, drowsiness, confusion, and even kidney failure or coma.
When the kidneys begin to fail and lose the ability to remove waste from the body, symptoms like weakness,
shortness of breath, itching, and leg swelling can arise. The American Cancer Society expects that in 2015
the United States will see approximately 26,850 new multiple myeloma diagnoses and 11,240 deaths from the
disease. Survival times range from 29 to 62 months once treatment has started (American Cancer Society
2015).
Some risk factors associated with multiple myeloma include age, gender, race, family history, and obesity.
There are very few myeloma patients under the age of 35 (less than one percent), and most multiple myeloma
patients are 65 years of age or older. Women are less likely to have myeloma than men, and African Americans
develop the disease at least twice as often as Caucasian Americans. While the majority of multiple myeloma
patients have no family history of the disease, individuals with a sibling or parent who has had multiple
myeloma are four times as likely to have the disease. Other risk factors include radiation exposure and
solitary plasmacytoma (American Cancer Society 2015).
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1.1 Biological Background
Multiple myeloma bone disease disrupts the body’s ability to maintain a healthy skeleton (American Cancer
Society 2015). Healthy bone continuously remodels itself in order to repair damaged bone, to adapt to
mechanical strains, and to gain access to minerals stored in the bone (Burr 2002; Parfitt 2002). The bone
remodeling process involves the removal of old, and perhaps damaged, bone and its replacement with new
bone. The primary actors in this process are cells called osteoclasts, osteoblasts, and osteocytes. Together,
the osteoclasts (which destroy bone) and osteoblasts (which form new bone) are called the basic multicellular
unit, or BMU (Bellido et al 2014).
Osteoclasts are responsible for bone removal (also called osteolysis or bone resorption). They are mult-
inucleated descendants of the hematopoietic monocyte-macrophage lineage. Once the remodeling process
has begun, hematopoeitic precursor cells are recruited to the BMU. Once there, the precursor cells differ-
entiate into preosteoclasts. Then, the mononuclear preosteoclasts join to form the multinucleated mature
osteoclast. These osteoclast precursor cells are recruited from their myeloid progenitors by macrophage
colony-stimulating factor (M-CSF), tumor necrosis factors (TNF), interleukin-6 (IL-6), receptor activator
of nuclear factor kappa-B ligand (RANKL), growth factors (GFs), and Activin A. Then mature osteoclast
recruitment from the preosteoclast population is regulated by osteocyte-secreted RANKL and osteoblast
secreted osteoprotegerin (OPG). Once bone resorption is complete, osteoclasts undergo apoptosis. While
the factors that stimulate apoptosis have not yet been completely determined, in vitro experiments have
shown that high calcium levels lead to osteoclast apoptosis (Bellido et al 2014).
Osteoblasts are responsible for the creation of new bone; they carry out bone matrix protein secretion and
bone mineralization. Osteoblasts are the descendants of mesenchymal stem cells and are characterized by a
cuboidal shape and a large nucleus located at the edge of the cell (Bellido et al 2014). As with osteoclasts,
osteoblast formation is regulated by chemical factors. Osteoclast-derived coupling factors recruit osteoblast
precursors from a pool of mesenchymal stem cells. Then the formation of mature osteoblasts is promoted by
insulin-like growth factor (IGF), transforming growth factor-β (TGFβ), and bone morphogenetic proteins
(BMPs) secreted by osteoclasts (Parfitt 1994; Bonewald and Dallas 1994; Plotkin and Bivi 2014). Once
new bone has been formed, 60%− 80% of osteoblasts undergo apoptosis. Some of the remaining osteoblasts
flatten and become lining cells. The rest become osteocytes (Bellido et al 2014; Bonewald 2011).
Approximately 5%-20% of osteoblasts become trapped in the bone and differentiate into osteocytes. They
are regularly dispersed throughout the mineralized bone and account for over 90% of the cells in the bone
matrix and on the surface of the bone (Bellido et al 2014; Bonewald 2011). Osteocytes are located in lacunae
and are connected by a network of dendritic processes, which are found in the canaliculi in the bone matrix.
The proteins produced by osteocytes are transported through this network of lacunae and canaliculi. Thus,
osteocytes can influence other cells within the bone matrix and on the surface of the bone (Buenzli 2015).
Recent studies have also shown that osteocytes play a key role in the regulation of osteoclasts and
osteoblasts (Bonewald 2011). They are able to identify damaged bone and induce osteoclastogenesis with
RANKL (Bellido et al 2014; Bonewald 2011). This happens in two ways. First, osteocytes going through
apoptosis cause oseoblasts and stromal cells to produce RANKL, thereby stimulating osteoclast recruitment.
Second, osteocytes can secrete RANKL themselves (Bellido et al 2014). Osteocytes also produce and secrete
sclerostin, which inhibits osteoblast recruitment by blocking the Wnt signaling pathway (Bonewald 2011;
Neve et al 2012; Kular et al 2012).
In healthy bone, the destruction of bone by osteoclasts is matched by the replacement of bone by os-
teoblasts so that bone mass is returned to its original state. However, in multiple myeloma patients, the bone
remodeling process is out of balance. In this unhealthy bone, bone destruction outpaces bone replacement,
leaving patients with bone lesions. These lesions are quite common in multiple myeloma patients; over ninety
percent of patients suffer from them. They occur most often in the spine, skull, pelvis, and ribs. Bone lesions
lead to pathologic fractures, bone pain, hypercalcemia, and spinal cord compression (Drake 2014). Even in
complete remission, multiple myeloma patients usually do not show reduction of skeletal lesions (Wahlin
et al 2009).
Multiple myeloma leads to bone lesions because myeloma tumor cells cause increased osteoclast produc-
tion, increased osteoclast activity levels, and decreased osteoblast production (Mundy et al 1974; Bataille
et al 1991; Valentin-Opran et al 1982; Evans et al 1989; Bataille et al 1990). This causes increased bone
resorption, which in turn encourages tumor growth. This is called the multiple myeloma “vicious cycle”
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(Abe et al 2004). This cycle is summarized in Figure 3. The details are shown more explicitly in Figure 10.
Myeloma tumor cells encourage this vicious cycle through several chemical factors. Several of these factors
encourage osteoclast production. Through adhesion betweeen vascular cell adhesion protein 1 (VCAM-1)
located on the stromal cells and very late antigen-4 (VLA4) located on the tumor cells, myeloma cells stimu-
late stromal RANKL production. This, in turn, simulates osteoclast formation (Michigami et al 2000; Mori
et al 2004). Myeloma cells further encourage osteoclast recruitment through the production of macrophage
inflammatory protein-1α (MIP-1α), tumor necrosis factor-α (TNF-α), and interleukin-3 (IL-3) (Silbermann
and Roodman 2013). Myeloma also causes osteocytes to secrete additional interleukin-11 (IL-11), stimulating
osteoclastogenesis (Giuliani et al 2012).
Myeloma cells also suppress the recruitment of osteoblasts. Some chemical factors secreted by myeloma
tumor cells that decrease osteoblast production are Dickkopf-related protein 1 (DKK1), IL-3, sclerostin, and
secreted frizzled-related proteins (sFRPs) (Drake 2014; Tian et al 2003; Ehrlich and Roodman 2005; Colucci
et al 2011; Oshima et al 2005). Additionally, tumor cells increase stromal cell production of Activin A,
leading to further decreased osteoblast production (Vallet et al 2010).
The other half of the multiple myeloma “vicious cycle” is the promotion of tumor growth by osteoclast
signaling. Osteoclasts secrete B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL),
which lead to increased tumor growth (Abe et al 2006).
1.2 Mathematical Background
Power law approximations are a method of representing biological systems pioneered by Savageau for bio-
chemical systems (Savageau 1969a,b, 1970, 1976; Voit 2000). They are equations of the form
dXi
dt
=
∑
j
γi
∏
k
X
gij
j ,
where the Xj are the populations present in the biological system and the γi and gij are parameters that
control the growth and decay of the populations. By expressing the power law instead as
dXi
dt
=
∑
j
αj
∏
k
Xgikk︸ ︷︷ ︸
growth
−
∑
j
βj
∏
k
Xhikk︸ ︷︷ ︸
decay
,
we separate the equation into two parts: one that promotes growth of the population and another that con-
tributes to decay. Each part of the equation is the product of a constant (αj or βj) and the cell populations
that contribute to the growth or decay raised to powers (gik or hik). This method is used by Komarova et al
(2003); Ryser et al (2009, 2010); Ayati et al (2010); Graham et al (2013), and it is used in the model we
present here.
We choose the more qualitatative or phenomenological power law approach over mechanistic models with
explicit biochemistry (Wang et al 2011; Eudy et al 2015; Ji et al 2015) for a number of reasons: the models
are much simpler mathematically; eventually they will be easier to parameterize from patient data; and
the fundamental relationships involved are more robust to changes in the understanding of the underlying
biochemistry. This last point is critical. A high fidelity mechanistic model, where the parameters are mostly
estimated, would indeed provide valuable and quantitatively precise information about the underlying rate
constants. However, if the mechanistic model is based on assumptions that later turn out to be false,
whatever claims that are made about the underlying rate constants will also turn out to be false. We are
operating under the assumption that the current consensus on the mechanisms underlying multiple myeloma
bone disease are subject to change.
The model in this paper advances prior work in two main ways. First, we add a number of additional
components we anticipate are necessary if a model is to be able to be used to predict patient outcomes
(compare Fig. 10 with Figs. 1, 3, 6). Second, we have a spatial model that includes cytokine diffusion and
and explicit presence of the tumor; the model presented by Graham et al (2012) used an implicit tumor
not located in any particular part of space. Other models based on ordinary differential equations have no
spatial heterogeneity (Ryser et al 2009, 2010; Wang et al 2011; Eudy et al 2015; Ji et al 2015).
3
2 Zero-Dimensional Models
Komarova et al (2003) used Savageau’s power law approximations to describe the dynamics of osteoclasts
and osteoblasts during a healthy bone remodeling event (without the presence of multiple myeloma tumor
cells). This model takes into account the autocrine and paracrine factors that contribute to the growth and
decay of these two cell populations. The model, based on the cell dynamics described in Figure 1, is
d
dt
C(t) = α1 C(t)
g11︸ ︷︷ ︸
autocrine
promotion
B(t)g21︸ ︷︷ ︸
paracrine
inhibition︸ ︷︷ ︸
osteoclast proliferation
− β1C(t),︸ ︷︷ ︸
osteoclast
removal
(1)
d
dt
B(t) = α2 C(t)
g12︸ ︷︷ ︸
paracrine
promotion
B(t)g22︸ ︷︷ ︸
autocrine
promotion︸ ︷︷ ︸
osteoblast proliferation
− β2B(t),︸ ︷︷ ︸
osteoblast
removal
(2)
d
dt
z(t) = −k1 max{0, C(t)− C¯}︸ ︷︷ ︸
the rate of bone resorption is proportional
to the number of osteoclasts
exceeding steady-state levels
+ k2 max{0, B(t)− B¯}.︸ ︷︷ ︸
the rate of bone formation is proportional
to the number of osteoblasts
exceeding steady-state levels
(3)
where C(t) is the density of osteoclasts, B(t) is the density of osteoblasts, and z is the total bone mass. C
and B represent the steady states for osteoclasts and osteoblasts, respectively. The steady state is given by
C =
(
β1
α1
)(1−g22)/Γ(β2
α2
)g21/Γ
,
B =
(
β1
α1
)g12/Γ(β2
α2
)(1−g11)/Γ
,
where Γ = g12g21 − (1 − g11)(1 − g22). Figure 2 shows the total bone mass (as a percentage) during a
simulation of a bone remodeling event initiated by an increase in osteoclasts.
Ayati et al (2010) expanded on Komarova et al.’s model by including the presence of a multiple myeloma
tumor. The new variables in this model are T (t) (the density of the tumor cells), LT (the maximum tumor
size), and γT (the tumor growth constant). The equations are
d
dt
C(t) = α1 C(t)
g11
(
1+r11
T (t)
LT
)
︸ ︷︷ ︸
increased autocrine
promotion of osteoclasts
B(t)
g21
(
1+r21
T (t)
LT
)
︸ ︷︷ ︸
decreased paracrine
inhibition of osteoclasts
−β1C(t), (4)
d
dt
B(t) = α2 C(t)
g12/
(
1+r12
T (t)
LT
)
︸ ︷︷ ︸
reduced paracrine
promotion of osteoblasts
B(t)
g22−r22 T (t)LT︸ ︷︷ ︸
reduced autocrine
promotion of osteoblasts
−β2B(t), (5)
d
dt
T (t) = γTT (t) log
(
LT
T (t)
)
,︸ ︷︷ ︸
Gompertz form
(6)
d
dt
z(t) = −k1 max{0, C(t)− C¯}+ k2 max{0, B(t)− B¯}. (7)
The parameters r11, r12, r21, and r21 are all nonnegative. Thus, the addition of the tumor to this model
increases osteoclast production and decreases osteoblast production. The steady state solution of this model
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is
C =
(
β1
α1
)(1−g22+r22)/Λ(β2
α2
)g21(1+r21)/Λ
,
B =
(
β1
α1
)g12/(Λ(1+r12))(β2
α2
)(1−g11(1+r11))/Λ
,
T = LT ,
where Λ = (g12/(1 + r12))(g21(1 + r21))−(1−g11(1 + r11))(1− g22 + r22). Computational results for this model
are shown in Figure 4. These results show increasing tumor size accompanied by increased osteoclast activity
(bone removal) and decreased osteoblast activity (bone replacement).
Ayati et al (2010) also introduce a model that includes treatment functions. These treatment functions,
V1(t) and V2(t), model the effects of proteasome inhibitors. Proteasome inhibitors promote osteoblast pro-
duction and inhibit tumor growth, thereby breaking the multiple myeloma “vicious cycle.” The treatment
model is
d
dt
C(t) = α1C(t)
g11
(
1+r11
T (t)
LT
)
B(t)
g21
(
1+r21
T (t)
LT
)
− β1C(t), (8)
d
dt
B(t) = α2C(t)
g12/
(
1+r12
T (t)
LT
)
B(t)
g22−r22 T (t)LT − (β2 − V1(t))︸ ︷︷ ︸
treatment function
promotes osteoblast
production
B(t), (9)
d
dt
T (t) = (γT − V2(t))︸ ︷︷ ︸
treatment function
inhibits tumor growth
T (t) log
(
LT
T (t)
)
, (10)
d
dt
z(t) = −k1 max{0, C(t)− C¯}+ k2 max{0, B(t)− B¯}. (11)
The treatment functions used in this model are given by
V1(t) =
{
0, t < tstart
v1, t ≥ tstart
V2(t) =
{
0, t < tstart
v2, t ≥ tstart.
Figure 5 shows computational results for this model. These results are similar to Figure 4 until t = 600,
when the treatment is introduced. At this time, the tumor density begins to shrink. At the same time, the
number of osteoclasts decreases and the number of osteoblasts increases. This leads to recovery of lost bone
mass.
3 Incorporating Osteocytes
Graham et al (2013) present a mathematical model of healthy bone remodeling that incorporates two ad-
ditional cell populations: osteocytes (Y (t)) and osteoblast precursors (BP (t)). The biological details of this
model are summarized in Figure 6. The equations for this model are
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dY
dt
= α1B
g31
(
1− Y
KY
)
+︸ ︷︷ ︸
recruitment of osteocytes from osteoblasts
that become embedded in the bone
(12)
dBP
dt
= α2Y
g21
(
1− Y
KY
)g22
+︸ ︷︷ ︸
differentiation of stem cells
to osteoblast precursors
by osteocyte signaling
+ α3B
g32
P
(
1− Y
KY
)
+︸ ︷︷ ︸
proliferation of osteoblast
precursors by autocrine signaling
(when not inhibited by sclerostin)
− β1Bf12P Cf14︸ ︷︷ ︸
differentiation of
osteoblast precursors to
osteoblasts by autocrine
and osteoclast signaling
− δBP︸︷︷︸
apoptosis
(13)
dB
dt
= β1B
f12
P C
f14︸ ︷︷ ︸
differentiation of osteoblast
precursors into osteoblasts
− β2Bf23︸ ︷︷ ︸
apoptosis
− α1Bg31
(
1− Y
KY
)
+︸ ︷︷ ︸
recruitment of osteocytes from osteoblasts
that become embedded in the bone
(14)
dC
dt
= α4Y
g41Bg42P (+B)
g43
(
1− Y
KY
)g44
+︸ ︷︷ ︸
differentiation of osteoclast precursors into
osteoclasts by the RANK/RANKL/OPG pathway
− β3Cf34︸ ︷︷ ︸
apoptosis
(15)
dz
dt
= −k1C︸ ︷︷ ︸
amount of bone removed
is proportional to the
number of osteoclasts
+ k2B︸︷︷︸
amount of bone formed
is proportional to the
number of osteoblasts
, (16)
where (x)+ = max{x, 0}.
In this model, KY represents the relationship between osteocyte apoptosis and the decrease in sclerotin
inhibition. The term
(
1− YKY
)
+
represents the effects of sclerotin and the Wnt/β-catenin pathway. That
is, when the number of osteocytes reaches KY , the sclerotin level is sufficient to block Wnt signaling. This
model assumes that osteocyte death is primarily governed by the initiation of the remodeling process. Thus,
no osteocyte apoptosis term is included.
4 One-Dimensional Bone Remodeling with Multiple Myeloma
Here we present a one-dimensional model of bone remodeling with the presence of multiple myeloma tumor
cells. Figure 9 is a simplified two-dimensional representation of a cross section of a bone marrow biopsy
core. A section of bone and a myeloma tumor lay within the marrow. Additionally, a remodeling site is
located on the edge of the bone. For our model we consider a one-dimensional representation of this spatial
environment, also shown in Figure 9.
This model builds upon the model presented in Graham et al (2013) by including additional cell popu-
lations, specifically osteoclast precursors (CP (t)), stromal cells (S(t)), and myeloma tumor cells (T (t)). The
interactions of the various cell populations included in this model are detailed in Figure 10. This model also
incorporates the effects of chemical factors that diffuse across the marrow during the remodeling process:
• LC(t): BAFF and APRIL, diffusing from the osteoclasts to the tumor cells
• LT1(t): MIP-1α, IL-3, and TNFα, diffusing from the tumor cells to the osteoclasts
• LT2(t): DKK1, IL-3, sclerostin, and sFRPs, diffusing from the tumor cells to the osteoblasts
• LS1(t): IL-6, RANKL, GFs, and Activin A, diffusing from the stromal cells to the osteoclasts
• LS2(t): Activin A, diffusing from the stromal cells to the osteoblasts
Additionally, the model includes a “moving boundary.” That is, the positions of the left and right endpoints
of the marrow (`(t) and r(t), respectively) are governed by the change in the bone mass and tumor density,
respectively. The equations for this model are
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∂S
∂t
= α1S
g11T g12︸ ︷︷ ︸
1
recruitment of stromal cells
by tumor signaling
− β1S︸︷︷︸
2
apoptosis
(17)
dT
dt
= α2 [S
g21 ]x=r T
g22︸ ︷︷ ︸
3
recruitment of tumor cells
by stromal cell signaling
+ α3T
g31 [Lg32C ]x=r︸ ︷︷ ︸
4
recruitment of tumor cells by
BAFF and APRIL signaling
− β2T f21︸ ︷︷ ︸
5
apoptosis
(18)
dCP
dt
= α4
[
Lg41S1
]
x=`︸ ︷︷ ︸
6
recruitment of osteoclast
precursors by stromal
cell signaling
− γ1(+B)h11
[
Lh12T1
]
x=`
(
1− Y
KY
)h13
+
Y h14Ch15P︸ ︷︷ ︸
7 − 9
differentiation of osteoclast precursors into osteoclasts
by the RANK/RANKL/OPG pathway
− β3CP︸ ︷︷ ︸
10
apoptosis
(19)
dC
dt
= γ1(+B)
h11
[
Lh12T1
]
x=`
(
1− Y
KY
)h13
+
Y h14Ch15P︸ ︷︷ ︸
7 − 9
differentiation of osteoclast precursors into osteoclasts
by the RANK/RANKL/OPG pathway
− β4C︸︷︷︸
11
apoptosis
(20)
dBP
dt
= α5C
g51︸ ︷︷ ︸
12
recruitment of
osteoblast precursors
by osteoclasts
+ α6z
g52︸ ︷︷ ︸
13
recruitment of osteoblast
precursors by IGF-1,
secreted by the bone matrix
(21)
− γ2Ch21
[
Lh22T2
]
x=`
[
Lh23S2
]
x=`
(
1− Y
KY
)h24
+
Y h25Bh26P︸ ︷︷ ︸
14 − 17
differentiation of osteoblast precursors into osteoblasts
− β5BP︸ ︷︷ ︸
18
apoptosis
dB
dt
= γ2C
h21
[
Lh22T2
]
x=`
[
Lh23S2
]
x=`
(
1− Y
KY
)h24
+
Y h25Bh26P︸ ︷︷ ︸
14 − 17
differentiation of osteoblast precursors into osteoblasts
− γ3Bh31
(
1− Y
KY
)h32
+︸ ︷︷ ︸
19
differentiation of osteoblasts
into osteocytes
− β6B︸︷︷︸
20
apoptosis
(22)
dY
dt
= γ3B
h31
(
1− Y
KY
)h32
+︸ ︷︷ ︸
19
differentiation of osteoblasts
into osteocytes
− β7Y︸︷︷︸
21
apoptosis
(23)
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∂LC
∂t
= δ11∇2LC − δ12LC︸ ︷︷ ︸
4
diffusion of BAFF and APRIL
from osteoclasts to tumor cells
(24)
∂LT1
∂t
= δ21∇2LT1 − δ22LT1︸ ︷︷ ︸
8
diffusion of MIP-1α, IL-3, and TNFα
from tumor cells to osteoclasts
(25)
∂LT2
∂t
= δ31∇2LT2 − δ32LT2︸ ︷︷ ︸
14
diffusion of DKK1, IL-3, sclerostin,
and sFRPs from tumor cells to osteoblasts
(26)
∂LS1
∂t
= δ41∇2LS1 − δ42LS1︸ ︷︷ ︸
6
diffusion of IL-6, RANKL, GFs
and Activin A from stromal cells
to osteoclast precursors
(27)
∂LS2
∂t
= δ51∇2LS2 − δ52LS2︸ ︷︷ ︸
15
diffusion of Activin A from
stromal cells to osteoblasts
(28)
dz
dt
= −k1C︸ ︷︷ ︸
amount of bone removed
is proportional to the
number of osteoclasts
+ k2B︸︷︷︸
amount of bone formed
is proportional to the
number of osteoblasts
(29)
d`
dt
= a
dz
dt︸︷︷︸
movement of the left
boundary is proportional to
the change in bone mass
(30)
dr
dt
= b
dT
dt︸︷︷︸
movement of the right
boundary is proportional to
the change in the tumor
(31)
where (x)+ = max{x, 0} =
{
x, x ≥ 0
0, x < 0.
The boxed numbers correspond with the cell signaling represented
in Figure 10.
Equation 17 describes the dynamics of the stromal cell population. The stromal cells (the connective
tissue cells of the bone marrow) are recruited by tumor cell signaling 1 at a rate α1. Stromal cell apoptosis
2 occurs at a rate β1.
Equation 18 describes the dynamics of the tumor cell population. Myeloma tumor cells are recruited by
stromal cell signaling 3 at the right endpoint of the marrow. This recruitment occurs at a rate α2. Tumor
cells are also recruited by osteoclast signaling of BAFF and APRIL 4 as a part of the multiple myeloma
“vicious cycle.” This recruitment occurs at a rate α3 and is due to the amount go these ligands present at
the right endpoint of the marrow. Finally, tumor cell apoptosis 5 occurs at a rate β2.
The dynamics of the osteoclast precursor cells are described in equation 19. This equation states that
osteoclast precursors descend from a pool of myeloid progenitors 6 at a rate α4. This differentiation is largely
influenced by stromal cell signaling at the left boundary point of the marrow. Additionally, this equation
states that osteoclast precursors differentiate into osteoclasts by the RANK/RANKL/OPG pathway 7 - 9
at a rate γ1. Finally, we have osteoclast precursor death 10 at a rate β3.
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Equation 20 describes the dynamics of the osteoclast population. This equation states the osteoclasts
differentiate from the pool of osteoclast precursors by the RANK/RANKL/OPG pathway 7 - 9 at a rate
γ1. Additionally, osteoclasts undergo apoptosis 11 at a rate β4.
Equation 21 describes the dynamic of the osteoblast precursor population. Osteoblast precursors dif-
ferentiate from a pool of mesenchymal stem cells due to osteoclast 12 and bone matrix 13 signaling.
Osteoblast precursors are recruited by osteoclasts at a rate α5 and by IGF-1 (secreted by the bone matrix)
at a rate α6. Additionally, osteoblast precursors differentiate into mature osteoblasts 14 - 17 at a rate γ2.
Finally, osteoblast precursors undergo apoptosis 18 at a rate β5.
The dynamics of mature osteoblasts are described by Equation 22. This equation states that osteoblast
precursors are differentiated into osteoblasts 14 - 17 at a rate γ2. Additionally, under this model, ma-
ture osteoblasts have one of two fates: differentiation into osteocytes 19 or cell death 20 . Osteoblasts
differentiate into osteocytes at a rate γ3 and undergo apoptosis at a rate β6.
Equation 23 describes the dynamics of the osteocyte population. This equation states that osteocytes
differentiate from the pool of osteoblasts 19 at a rate γ3. These cells undergo apoptosis 21 at a rate β7.
Equations 24-28 describe the diffusion of chemical factors across the bone marrow. Each of these equations
is a diffusion equation of the form dLidt = δil∇2Li − δi2Li, where ∇2 is the Laplace operator.
Equation 29 gives the rate of change of the bone mass. This equation states that bone resorption is
proportional to the number of osteoclasts (with proportionality constant k1). Similarly, bone formation is
proportional to the number of osteoblasts (with proportionality constant k2).
Equations 30 and 31 describe the movement of the bone/marrow interface and the marrow/tumor inter-
face, respectively. The bone/marrow interface (`(t)) moves to the left as the bone mass decreases. Similarly,
the marrow/tumor interface (r(t)) move to the left as the tumor grows.
5 Results
Equations 17 - 31 were solved using MATLAB’s pdepe function CITE with the parameter and initial condition
values listed in Table 4. The diffusion values (δi1) were computed based on the relationship between the size
of the peptides (Stokes radius) and the known diffusion values:
(Stokes Radius) = 0.0156(molecular weight) + 1.527
(diffusion constant) = −4× 10−7(Stokes Radius) + 2× 10−6
The computed values for each ligand are given in Table 5 The simulation represents a myeloma-dysregulated
bone remodeling event taking place over 75 days. The results are shown in Figures 11, 12, and 13.
Figure 11 gives the bone cell counts and bone mass percentage for the simulated bone remodeling event.
Figure 11(a) shows the dynamics of the stromal cell population at position x = 0. The dynamics of this
population at all other positions are similar to those shown in Figure 11(a). Throughout the remodeling
event, we see an increase in the number of stromal cells. figure 11(b) shows the dynamics of the multiple
myeloma tumor cell population. For the first fifty days of the bone remodeling event, there is no significant
change in the number of tumor cells. However, in the last twenty-five days of the event we see an increase
in the tumor cell population due to the multiple myeloma “vicious cycle.” Figures 11(c) and 11(d) show
the dynamics of the osteoclast precursor and mature osteoclast cell populations. Both populations decrease
as the remodeling event continues. Figures 11(e) and 11(f) show the dynamics of the osteoblast precursor
and mature osteoblast cell populations. The osteoblast precursor population decreases in size quickly as
osteoblast precursors are recruited to the mature osteoblast population. Figure 11(g) shows the dynamics of
the osteocyte population. There is an initial decrease in the number of osteocytes due to the initiation of the
bone remodeling event. However, as the event continues, the number of osteocytes begins to increase due to
the creation of new bone. Figure 11(h) shows the percentage of bone mass throughout the bone remodeling
event. As the remodeling event progresses and the tumor cell population grows, the bone mass percentage
decreases.
Figure 12 shows the diffusion of ligands across the marrow. Figure 12(a) shows the diffusion of BAFF
and APRIL from the osteoclasts to the tumor cells. Figure 12(b) shows the diffusion of MIP-1α, IL-3, and
TNFα from the tumor cells to the osteoclasts. Figure 12(c) shows the diffusion of DKK1, IL-3, sclerotin,
9
and sFRPs from the tumor cells to the osteoblasts. Figure 12(d) shows the diffusion of IL-6, RANKL, GFs,
and Activin A from the stromal cells to the osteoclasts. Figure 12(e) shows the diffusion of Activin A from
the stromal cells to the osteoblasts.
Figure 13 shows the movement of the bone/marrow interface and the marrow/tumor interface. At
time t = 0, the bone/marrow interface is at x = −1 and the marrow/tumor interface is at x = −1. As
time progresses, the bone recedes and the tumor grows. At time t = 75, the bone/marrow interface is at
x = −1.2999 and the marrow/tumor interface is at x = 0.5820.
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Figure 1: Diagram of the chemical signals between osteoclasts and osteoblasts, as described by Komarova
et al (2003). The parameters are also taken from Komarova et al (2003): g11 (autocrine promotion of osteo-
clasts), g12 (paracrine promotion of osteoclasts), g21 (paracrine inhibition of osteoclasts), and g22 (autocrine
promotion of osteoblasts)
Symbol Definition
C(t) Number of osteoclasts at time t
B(t) Number of osteoblasts at time t
C Number of osteoclasts in the steady-state
B Number of osteoblasts in the steady-state
z(t) Percentage of bone mass at time t
T (t) Number of tumor cells at time t
LT Maximum tumor size
γT Tumor growth constant
V1(t), V2(t) Treatment functions
Table 1: Definitions of symbols used in Section 2
Symbol Definition
Y (t) Number of osteocytes at time t
BP (t) Number of osteoblast precursors at time t
B(t) Number of osteoblasts at time t
C(t) Number of osteoclasts at time t
z(t) Percentage of bone mass at time t
KY Osteocyte population threshold for sclerostin production
Table 2: Definitions of symbols used in Section 3
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Figure 2: Simulation of a healthy bone remodeling event (Equations 1-3) using the following parameter
values: α1 = 3, α2 = 4, β1 = 0.2, β2 = 0.02, g11 = 0.5, g12 = 1, g21 = −0.5, g22 = 0, k1 = 0.24, k2 = 0.0017.
The simulation was completed with MATLAB’s ode15s with initial conditions C(0) = 15, B(0) = 316, and
z(0) = 100 (Komarova et al 2003)
Symbol Definition
S(t) Number of stromal cells at time t
T (t) Number of tumor cells at time t
CP (t) Number of osteoclast precursors at time t
C(t) Number of osteoclasts at time t
BP (t) Number of osteoblast precursors at time t
B(t) Number of osteoblasts at time t
Y (t) Number of osteocytes at time t
LC(t) BAFF and APRIL, diffusing from the osteoclasts to the tumor cells
LT1(t) MIP-1α, IL-3, and TNFα, diffusing from the tumor cells to the osteoclasts
LT2(t) DKK1, IL-3, sclerostin, and sFRPs, diffusing from the tumor cells to the osteoblasts
LS1(t) IL-6, RANKL, GFs, and Activin A, diffusing from the stromal cells to the osteoclasts
LS2(t) Activin A, diffusing from the stromal cells to the osteoblasts
z(t) Percentage of bone mass at time t
`(t) Position of the bone/marrow interface at time t
r(t) Position of the marrow/tumor interface at time t
KY Osteocyte population threshold for sclerostin production
Table 3: Definitions of symbols used in Section 4
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Figure 3: Diagram of the chemical signals between osteoclasts, osteoblasts, and myeloma tumor cells, as
described by Ayati et al (2010). The parameters g11, g12, g21, and g22 are as in Figure 1. Arrow (i)
represents the suppression of osteoblast production by myeloma tumor cells. Arrow (ii) represents the
increased osteoclast production and activity levels resulting from tumor signaling. Arrow (iii) represents
the increased tumor growth resulting from osteoclast activity. Together, arrows (ii) and (iii) comprise the
multiple myeloma “vicious cycle”
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Figure 4: Simulation of a bone remodeling event with the presence of multiple myeloma tumor cells (Equa-
tions 4-7) with the following parameter values: α1 = 3, α2 = 4, β1 = 0.2, β2 = 0.02, g11 = 1.1, g12 = 1,
g21 = −0.5, g22 = 0, k1 = 0.0748, k2 = 0.0006395, γT = 0.005, LT = 100, r11 = 0.005, r21 = 0, r12 = 0,
and r22 = 0.2. The simulation was completed with MATLAB’s ode23t with initial conditions C(0) = 15,
B(0) = 316, z(0) = 100, and T (0) = 1 (Ayati et al 2010)
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Figure 5: Simulation of a bone remodeling event with the presence of multiple myeloma tumor cells and
treatment (Equations 8-11) with the following parameter values: α1 = 3, α2 = 4, β1 = 0.2, β2 = 0.02,
g11 = 1.1, g12 = 1, g21 = −0.5, g22 = 0, k1 = 0.0748, k2 = 0.0006395, γT = 0.005, LT = 100, r11 = 0.005,
r21 = 0, r12 = 0, r22 = 0.2, tstart = 600, v1 = 0.001, and v2 = 0.008. The simulation was completed with
MATLAB’s ode15s with initial conditions C(0) = 13, B(0) = 300, z(0) = 100, and T (0) = 1. The steady
states are taken to be C = 5 and B = 316 (Ayati et al 2010)
Figure 6: Wiring Diagram used by Graham et al (2013)
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Figure 7: Population dynamics during a bone remodeling event (without the presence of a tumor), as
simulated by Graham et al (2013)
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Figure 8: Bone volume dynamics during a bone remodeling event (without the presence of a tumor), as
simulated by Graham et al (2013)
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Figure 9: Diagram of the bone marrow microenvironment. A section of the bone and a multiple myeloma
tumor are separated by the marrow. A remodeling site (with osteoclasts, osteoblasts, and osteocytes) is
located on the edge of the bone
21
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Figure 11: Computational results for Equations 17 - 31. This simulation represents a myeloma-dysregulated
remodeling event taking place over 75 days
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Figure 12: Computational results for Equations 17 - 31. This simulation represents a myeloma-dysregulated
remodeling event taking place over 75 days
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Figure 13: Computational results for Equations 17 - 31. This simulation represents a myeloma-dysregulated
remodeling event taking place over 75 days
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Parameter Value Parameter Value
α1 0.005 KY 10
α2 0.0003  1
α3 0.0001 g11 1
α4 0.01 g12 1
α5 0.01 g21 1
α6 0.01 g22 1
β1 0.01 g31 1
β2 0.008 g32 1
β3 0.01 g41 1
β4 0.01 g51 1
β5 0.01 g52 1
β6 0.01 h11 -1
β7 0.1 h12 1
γ1 0.01 h13 1
γ2 38.4 h14 1
γ3 0.00390625 h15 1
δ11 0.1037 h21 1
δ12 0.01 h22 -0.8
δ21 0.1210 h23 -0.8
δ22 0.01 h24 -0.8
δ31 0.1037 h25 -0.8
δ32 0.01 h26 1
δ41 0.1728 h31 1
δ42 0.01 h32 0.5
δ51 0.1063 f21 0.65
δ52 0.01 a 0.01
k1 0.1 b -0.03
k2 0.01
Table 4: Parameter values used in Section 4
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Peptide Molecular
Weight
(kDa)
Diffuusion
Coefficient
(Literature)
(cm2/sec)
Stokes
Radius
(nm)
Diffusion
Coefficient
(Calculated)
(cm2/sec)
IL-2 15.1 1.0× 10−6 1.602 1.36× 10−6
IL-3 16.2 1.0× 10−6 1.6328 1.35× 10−6
IL-6 23.7 9.0× 10−7 1.9628 1.21× 10−6
RANKL 35 2.073 1.17× 10−6
OPG 60 2.463 1.01× 10−6
BAFF 31 2.0106 1.20× 10−6
APRIL 28 1.9638 1.21× 10−6
MIP-1α 8 1.272 1.49× 10−6
TNF 17 1.668 1.33× 10−6
DKK-1 26 1.9326 1.23× 10−6
Sclerostin 23 9.0× 10−7 1.932 1.23× 10−6
sFRP-1 33 2.0418 1.18× 10−6
GFs 2.00× 10−6
Activin A 26.2 1.93572 1.23× 10−6
Hemoglobin 68 6.9× 10−7
Table 5: Table of known and calculated diffusion coefficients.
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